Golidocitinib, a selective JAK1 tyrosine-kinase inhibitor, in patients with refractory or relapsed peripheral T-cell lymphoma (JACKPOT8 Part B): a single-arm, multinational, phase 2 study
Titel:
Golidocitinib, a selective JAK1 tyrosine-kinase inhibitor, in patients with refractory or relapsed peripheral T-cell lymphoma (JACKPOT8 Part B): a single-arm, multinational, phase 2 study
Auteur:
Song, Yuqin Malpica, Luis Cai, Qingqing Zhao, Weili Zhou, Keshu Wu, Jianqiu Zhang, Huilai Mehta-Shah, Neha Ding, Kaiyang Liu, Yao Li, Zengjun Zhang, Liling Zheng, Meifang Jin, Jie Yang, Haiyan Shuang, Yuerong Yoon, Dok Hyun Gao, Sujun Li, Wenyu Zhai, Zhimin Zou, Liqun Xi, Yaming Koh, Youngil Li, Fei Prince, Miles Zhou, Hui Lin, Lie Liu, Hui Allen, Pamela Roncolato, Fernando Yang, Zhenfan Kim, Won-Seog Zhu, Jun